[Use of contrast agent in high-field MRI (3 T)].

The basic diagnostic efficacy of MR contrast medium in the evaluation of primary brain tumors and its clinical usefulness in the detection of brain metastases with single and cumulative triple-dose was compared using a high-field 3 T MR unit and a 1.5 T MR unit. Additionally, the effect of contrast agent on high-resolution MR venography based on the BOLD effect was evaluated at both field strengths. Tumor-brain contrast after gadodiamide administration, as assessed by means of statistical evaluation of MP-RAGE scans and T1-SE images, was significantly higher at 3 T than at 1.5 T. The subjective assessment of cumulative triple-dose 3 T images obtained the best results in the detection of brain metastases, followed by 1.5 T cumulative triple-dose enhanced images. Due to higher spatial resolution, contrast-enhanced MR venography at 3 T showed more details in and around tumors than at 1.5 T, additionally enhanced by stronger susceptibility weighting and higher signal-to-noise ratio at 3 T. In summary, administration of gadolinium-based contrast agent produces higher contrast between tumor and normal brain at 3 T than at 1.5 T, helps to detect more cerebral metastases at 3 T than at 1.5 T in single and cumulative triple dose, and improves MR venography at 3 T with increase in spatial resolution within the same measurement time, thus providing more detailed information.

RCT Entities:   Population Interventions Outcomes